NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. FLGT on behalf of long-term shareholders following a class action lawsuit filed against Fulgent on September 20, 2022 with a class action dated March 22, 2019 and ending on August 4, 2022. Our investigation concerns whether Fulgent’s board of directors breached their class action fiduciary duties to the company.

On August 4, 2022, Fulgent reported its second quarter 2022 financial results and announced that the SEC is investigating certain of Fulgent’s reports filed with the SEC from 2018 through the first quarter of 2020. The disclosure follows Fulgent’s receipt of a civil investigation request issued by the U.S. Department of Justice “in connection with its investigation into allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and compensation received or provided in violation of the Anti-Kickback Statute and Stark Act became”.

As a result of this news, Fulgent’s stock price fell $11.02, or 17.29%, in the following two trading sessions to close on August 8, 2022 at $52.72 per share.

If you are a long-time Fulgent shareholder, have any information, would like to learn more about these allegations, or have any questions about this announcement or your rights or interests related to these matters, please email Brandon Walker or Melissa Fortunato at investigations@bespc.comby phone at (212) 355-4648 or by fill out this contact form. There are no costs or obligations for you.

About Bragar Eagle & Squire, PC:

Bragar Eagel & Squire, PC is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivatives and other complex litigation in state and federal courts across the country. For more information about the company, visit…